Maze Therapeutics (MAZE) Retained Earnings (2024 - 2026)

Maze Therapeutics has reported Retained Earnings for 3 years, with the latest figure at $855.5 million in Q1 2026.

• Quarterly Retained Earnings rose 25.22% year-over-year to $855.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $855.5 million (up 25.22% YoY) and the FY2025 annual result came in at -$489.5 million, down 36.58% from the prior year.
• Retained Earnings advanced to $855.5 million in Q1 2026 per MAZE's latest filing, from -$489.5 million in the prior quarter.
• Over five years, Retained Earnings peaked at $855.5 million in Q1 2026 and troughed at -$489.5 million in Q4 2025.
• A 3-year average of $153.8 million and a median of $162.4 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings plunged 36.58% in 2025, then gained 25.22% in 2026.
• Over 3 years, Retained Earnings stood at -$358.4 million in 2024, then sank by 36.58% to -$489.5 million in 2025, then soared by 274.76% to $855.5 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $855.5 million, -$489.5 million, and -$455.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.